Logo image of CPHI

CHINA PHARMA HOLDINGS INC (CPHI) Stock Fundamental Analysis

NYSEARCA:CPHI - US16941T4013 - Common Stock

1.675 USD
+0.24 (+16.32%)
Last: 9/5/2025, 8:05:49 PM
1.63 USD
-0.05 (-2.69%)
After Hours: 9/5/2025, 8:05:49 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to CPHI. CPHI was compared to 195 industry peers in the Pharmaceuticals industry. CPHI may be in some trouble as it scores bad on both profitability and health. CPHI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CPHI has reported negative net income.
In the past year CPHI had a positive cash flow from operations.
In the past 5 years CPHI always reported negative net income.
In the past 5 years CPHI always reported negative operating cash flow.
CPHI Yearly Net Income VS EBIT VS OCF VS FCFCPHI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -32.12%, CPHI is in line with its industry, outperforming 48.72% of the companies in the same industry.
The Return On Equity of CPHI (-65.51%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -32.12%
ROE -65.51%
ROIC N/A
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
CPHI Yearly ROA, ROE, ROICCPHI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CPHI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CPHI Yearly Profit, Operating, Gross MarginsCPHI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CPHI has more shares outstanding
The number of shares outstanding for CPHI has been increased compared to 5 years ago.
Compared to 1 year ago, CPHI has a worse debt to assets ratio.
CPHI Yearly Shares OutstandingCPHI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
CPHI Yearly Total Debt VS Total AssetsCPHI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -4.88, we must say that CPHI is in the distress zone and has some risk of bankruptcy.
CPHI has a Altman-Z score (-4.88) which is in line with its industry peers.
A Debt/Equity ratio of 0.50 indicates that CPHI is somewhat dependend on debt financing.
The Debt to Equity ratio of CPHI (0.50) is worse than 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Altman-Z -4.88
ROIC/WACCN/A
WACC7.9%
CPHI Yearly LT Debt VS Equity VS FCFCPHI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

CPHI has a Current Ratio of 0.56. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
CPHI's Current ratio of 0.56 is on the low side compared to the rest of the industry. CPHI is outperformed by 92.31% of its industry peers.
CPHI has a Quick Ratio of 0.56. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
CPHI has a worse Quick ratio (0.17) than 94.87% of its industry peers.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.17
CPHI Yearly Current Assets VS Current LiabilitesCPHI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.31% over the past year.
The Revenue for CPHI has decreased by -33.10% in the past year. This is quite bad
Measured over the past years, CPHI shows a very negative growth in Revenue. The Revenue has been decreasing by -16.15% on average per year.
EPS 1Y (TTM)72.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.56%
Revenue 1Y (TTM)-33.1%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%-17.06%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CPHI Yearly Revenue VS EstimatesCPHI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CPHI Price Earnings VS Forward Price EarningsCPHI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CPHI Per share dataCPHI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CPHI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINA PHARMA HOLDINGS INC

NYSEARCA:CPHI (9/5/2025, 8:05:49 PM)

After market: 1.63 -0.05 (-2.69%)

1.675

+0.24 (+16.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-25 2022-11-25/amc
Earnings (Next)N/A N/A
Inst Owners1.04%
Inst Owner Change-62.23%
Ins Owners19.05%
Ins Owner Change0%
Market Cap5.46M
Analysts0
Price TargetN/A
Short Float %0.47%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.27
P/FCF N/A
P/OCF 89.81
P/B 0.78
P/tB 13.65
EV/EBITDA N/A
EPS(TTM)-2.31
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)0.02
OCFY1.11%
SpS1.32
BVpS2.14
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.12%
ROE -65.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.84%
Cap/Sales 8.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.17
Altman-Z -4.88
F-Score2
WACC7.9%
ROIC/WACCN/A
Cap/Depr(3y)8.82%
Cap/Depr(5y)14.6%
Cap/Sales(3y)3.86%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.1%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%-17.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-35.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y106.09%
OCF growth 3YN/A
OCF growth 5YN/A